Pfizer is getting closer to gaining regulatory approval for an investigational leukemia treatment called inotuzumab ozogamicin.
British-based pharmaceutical firm AstraZeneca may be gaining an advantage in the burgeoning PARP inhibitor drug space.
Boston-based Rhythm Pharmaceuticals obtained a new round of funding to help continue development of its lead peptide therapy setmelanotide.
A promising multiple sclerosis treatment called Ocrevus will play a crucial role in this growth.
Investigators will gain a five-year appointment and up to $1.5 million in funding to kick start their research projects.
Another drug company reignited the debate over appropriate pricing policies for important medications.
More than 150 biotech CEOS, venture capitalists and startup founders signed a letter to the President expressing their deep concern and opposition to the order.
British-based GW Pharmaceuticals received more good news regarding its cannabis-based drug development efforts.
Investigators running this randomized, double-blind, placebo-controlled trial recruited 150 elderly patients diagnosed with acute myeloid leukemia.
Bristol-Myers Squibb’s prized immuno-oncology drug gained another label expansion.
Another drug company unveiled a new strategy for dealing with the drug pricing debate.
The government is working on new strategies to ensure pharmaceutical and biotech R&D can thrive in the country after the process is completed.
The lobbying group began laying the groundwork for this program several months ago in the midst of the election.
Celgene expanded its autoimmune disease pipeline with a new acquisition.
MDX has traversed a difficult path during the research and development process.
President-elect Donald Trump went after the pharmaceutical industry in the opening remarks of his first press conference since the election.
The Cambridge, Massachusetts-based biotech company has kept its pipeline a secret until now.
Japanese drugmaker Takeda acquired Boston-based Ariad Pharmaceuticals, a biotech company specializing in cancer drugs.
The biotech startup wants to use this new funding to advance development of its specialized early detection cancer test.
The Foster City, California-based biotech added a top cancer specialist to its executive ranks.
An analysis published by Deloitte’s Centre for Health Solutions indicated the pharmaceutical industry experienced a continued decline in R&D returns for...
Other researchers have used similar methods to sift through large amounts of data in order to pinpoint promising compounds to treat diseases.
These articles provide a snapshot of the change the pharmaceutical industry experienced throughout the year.
A new report explains how hospitals are implementing aggressive new measures to cut pharmaceutical spending in the face of rapidly rising prices for certain...
Novartis is bolstering its dermatology portfolio with a new acquisition.
Voyager Therapeutics is testing an experimental gene therapy that could boost Parkinson’s patients’ responses to levodopa.
Eli Lilly will launch a new program in conjunction with Express Scripts to offer diabetes patients lower prices for its insulin products.
Bayer in conjunction with Versant Ventures are investing up to $225 million in a startup called Bluerock Therapeutics in one of the largest Series A funding...
Biogen reported more encouraging data for its experimental Alzheimer’s treatment aducanumab on Thursday.
The transition team for President-elect Donald Trump is reportedly exploring an unusual pick to run the Food and Drug Administration.
Part of this restructuring process will include cutting less than 10 percent of its global workforce.
Heather Bresch came to the fifth annual Forbes Healthcare conference to talk about the fallout from the EpiPen pricing controversy.
This condition produces mutations that lead to a serious shortage of white blood cells.
Approximately 400,000 people all over the world are living with either hemophilia A or hemophilia B.
An experimental Alzheimer’s drug being developed by Eli Lilly failed to slow cognitive decline in patients with even a mild form of the condition.
Novartis is boosting its hematology pipeline with a new acquisition.
Amgen and Novartis are one step closer to having a contender in the migraine treatment space.
Amgen announced good news for its cholesterol drug Repatha at the annual American Heart Association meeting taking place in New Orleans.
Drug makers are working with companies like Propeller Health on these devices because they could provide improved adherence and better health outcomes.